Categories
news

AEL Gets SBA Loan Fraud Case Dismissed

In May 2022, AEL won another dismissal of criminal charges filed against one of its clients, this time of state criminal charges filed by the State of New Jersey (Hudson County). The criminal complaint, filed in January 2022, levied felony charges against the client for allegedly misappropriating approximately $150,000 in SBA loan funds provided in response to the COVID-19 pandemic, including funds from the federal Paycheck Protection Program (PPP) and the SBA’s Economic Injury Disaster Loan (EIDL) program. AEL confronted the charges directly, providing evidence, records and information to the Hudson County Prosecutor’s Office that the client had properly applied, was eligible for, and used the funds in compliance with SBA’s rules and regulations. On May 16, 2022, the State dismissed all charges filed against the client. Both the client and his AEL family are thrilled with the result. This case was handled by AEL partner David M. Eskew.

Since the inception of federal loan programs to aid businesses and employers in the wake of the COVID-pandemic, the Government has warned would-be fraudsters that robust enforcement action was forthcoming. Indeed, a recent NY Times article indicated that the Government had at least “500 people working on pandemic-fraud cases,” not including investigators from the FBI, U.S. Secret Service, the U.S. Postal Inspection Service, and the IRS. The article also indicated that the federal government had already charged some 1,500 individuals with pandemic-aid fraud and that there were tens of thousands of ongoing and open investigations. President Biden recently signed a bill extending the statute of limitations for pandemic-aid fraud to ten years to permit the Government additional time to investigate and prosecute pandemic loan fraud. Needless to say, the wave of government enforcement action related to COVID-19 pandemic loan fraud has only just begun to rise and has not nearly crested.

AEL has and is representing clients in both federal and state investigations relating to both alleged pandemic loan fraud and other alleged fraud relating to federal programs. This incredible result, and others that we have obtained in both charged and uncharged cases, highlights AEL’s expertise in government programs generally, including the Medicare, Medicaid, and Tricare programs, the PPP, SBA loan programs, and fraud in connection with Service-Disabled Veteran-Owned Businesses (SDVOB). In obtaining the dismissal above, AEL employed its signature evidence-based approach to confront the charges head on and bring about the best possible resolution as efficiently as possible.

Categories
news

Best Lawyers in America 2023 Honors Two AEL Attorneys

AEL is proud to announce that, on August 18, 2022, two of our attorneys were named to the 2023 lists of Best Lawyers in America.

Scott R. Landau was once again awarded with the honor of being ranked as a “Best Lawyer” in the category of Health Care Law. With a specialty in healthcare regulation, Scott advises healthcare clients on complex compliance issues, negotiates and structures sophisticated transactions, defends institutions and individuals in government enforcement matters, represents providers in insurance inquiries and audits, conducts sensitive internal investigations, and litigates complex commercial and civil disputes. Scott has vast experience in healthcare law, having previously served as Associate General Counsel for the Mount Sinai Health System focusing on healthcare regulatory matters, and before that, as an Assistant U.S. Attorney for the Eastern District of New York, where he specialized in healthcare fraud and enforcement matters.  Since January 2020, when he co-founded AEL with Kenneth Abell and David Eskew, Scott’s practice has focused almost exclusively on helping healthcare providers and healthcare adjacent concerns with their most pressing issues.   

Julia H. Sear, Associate, was listed as a “Best Lawyer: Ones to Watch” in Commercial Litigation. Through her work at AEL, Julia provides stellar counsel to clients for a variety of matters, including in-depth investigations, commercial disputes, intellectual property, antitrust and real estate matters. Prior to her joining AEL, Julia served as an Assistant District Attorney at the Manhattan DA’s Office, where she tried several cases, and at a large nationally-recognized firm.

About Best Lawyers

The Best Lawyers in America list, having been published for more than three decades, is one of the most reputable and recognized rankings of attorneys across the nation. Those honored on the list are divided by geographic region and practice area(s) and their work undergoes a significant peer review process.

Best Lawyers: Ones to Watch in America recognizes associates and other attorneys who are at earlier stages of their careers for their impressive performance and professional excellence in private practice. Although slightly newer than the traditional The Best Lawyers in America list, Ones to Watch utilizes the same robust peer-review process and methodology.

To learn more about the review process utilized by Best Lawyers, please click here.

Categories
news

AEL and Individual Partners Recognized in Multiple Categories in 2022 Chambers USA Guide

Abell Eskew Landau LLP (AEL) is pleased to announce that the Firm and all three of its partners were recognized in the 2022 Chambers USA Guide in multiple categories.

In the 2022 Guide, Chambers noted AEL’s “meteoric rise. They are one of the top-tier groups for healthcare white-collar matters and have put together a very talented group of lawyers.” Chambers ranked AEL alongside some of the nation’s largest and most prestigious firms in the categories of Healthcare (NY); Litigation: White-Collar Crime & Government Investigations (NJ); and Litigation: Specialist Firms in White-Collar Crime & Government Investigations (NY).

Chambers quoted AEL’s clients regarding both the Firm generally and its individual partners. One client described Scott Landau as “a terrific lawyer; very knowledgeable, practical and easy to work with.” Clients described David Eskew as “practical and smart” with “great judgment.” “He has a deep knowledge of government investigations relating to healthcare and the False Claims Act.”

Another client commented about AEL’s representation, “I was impressed by the thoughtfulness of approach and efficiency in delivering first-rate results at an affordable price.” AEL is particularly gratified with our clients’ recognition not only of our subject matter expertise in the areas of healthcare and white-collar crime and investigations, but also our “small-firm” approach to practicality, collaboration, and efficiency.

The complete rankings by Chambers USA are listed below:

Abell Eskew Landau

  • Healthcare (NY) – Band 5
  • Litigation: White-Collar Crime & Government Investigations (NJ) – Band 3
  • Litigation: Specialist Firms in White-Collar Crime & Investigations (NY) – Band 3

Kenneth M. Abell

  • Healthcare (NY)

David M. Eskew

  • Healthcare (NY)
  • Litigation: White-Collar Crime & Government Investigations (NY)
  • Litigation: White-Collar Crime & Government Investigations (NJ)

Scott R. Landau

  • Healthcare (NY)

Chambers & Partners is an independent research company delivering detailed rankings and insight into the world’s leading lawyers. Chambers describes its independent rankings as “central to everything we do and are why our research is the industry leader. It is our rigorous independent processes that makes Chambers the gold standard in legal insight.”

To view AEL’s Chambers rankings and profile, click here.

Categories
news

Law360 Publishes Article by Scott R. Landau Opining on Recent Medtronic Decision Relating to AKS Safe Harbors in Expert Analysis Section

On March 10, 2022, Law360 published an article authored by partner Scott R. Landau in their Expert Analysis Section. The article discusses the recent decision in U.S. v. Medtronic PLC in the Central District of California that casts a shadow over the conventional wisdom that the safe harbors to the Anti-Kickback Statute (AKS) protect certain payment practices from liability regardless of the intent of the parties. As discussed in the article, the view expressed could be used to narrow the protections of the safe harbors and undermine the certainty they were meant to provide. The full article can be found on our Law Blog or on Law360.  

Categories
blog

Anti-Kickback Safe Harbors May Be Less Safe After Medtronic

The following article was originally published on March 10, 2022 in the Expert Analysis section of Law360 and was authored by AEL partner Scott R. Landau.

It has long been the conventional wisdom that the safe harbors to the Anti-Kickback Statute (AKS) protect certain payment practices from liability, regardless of the intent of the parties. A February order issued by the U.S. District Court for the Central District of California in U.S. v. Medtronic PLC, a False Claims Act (FCA) qui tam case predicated on alleged AKS violations, however, casts doubt on this view, and could trigger the erosion of the very protections the safe harbors are meant to provide.

The AKS and the Safe Harbors

The AKS is a federal criminal law that prohibits the knowing and willful payment of remuneration to induce or reward patient referrals or the generation of business involving any item or service payable by federal health care programs. 42 U.S.C. § 1320a-7b. AKS violations are subject to criminal penalties and administrative sanctions including fines, imprisonment and exclusion from participation in federal healthcare programs. See 42 U.S.C. § 1320a-7b(b); 42 U.S.C. § 1320a-7. Claims for payment from federal health care programs that are tainted by AKS violations are also actionable civilly under the FCA. See 42 U.S.C. § 1320a-7b(g).

Because of the broad reach of the AKS, following its implementation concerns were raised that certain commercial arrangements that should be outside its purview “were technically covered by the statute and therefore were subject to criminal prosecution.” See Medicare and State Health Care Programs: Fraud and Abuse; Clarification of the Initial OIG Safe Harbor Provisions and Establishment of Additional Safe Harbor Provisions Under the Anti-Kickback Statute, 64 FR 63518-01 (Nov. 19, 1999). As a result, in 1987 Congress enacted the Medicare and Medicaid Patient and Program Protection Act. See Public Law 100-93 (section 1128B(b)(3)(E)); 42 U.S.C. 1320a-7b(B)(3)(E)). The act tasked the U.S. Department of Health and Human Services to develop safe harbor provisions to “specify various payment and business practices that would not be subject to sanctions under the anti-kickback statute, even though they may potentially be capable of inducing referrals of business under the Federal health care programs.” Medicare and State Health Care Programs: Fraud and Abuse; Electronic Health Records Safe Harbor Under the Anti-Kickback Statute, 78 FR 79202-01 (Dec. 27, 2013).

Based on that mandate, HHS promulgated regulations establishing a number of safe harbors for certain arrangements that remove them from the scope of the AKS. United States ex rel. Baklid v. Halifax Hospital Medical Ctr. , No. 6:09-cv-1002-Orl, 2013 WL 6196562, *6 (M.D. Fla. Nov. 26, 2013). The regulations, codified at Title 42 of the Code of Federal Regulations, Section 1001.952, identify certain so-called payment practices that “shall not be treated as a criminal offense under … the Act and shall not serve as the basis for an exclusion” so long as the criteria enumerated therein are met. Id.

Importantly, in establishing the regulations, HHS “sought to specify particular safe harbors, that, despite the potentially unlawful intent, would protect non-abusive relationships.” Medicare and State Health Care Programs: Fraud and Abuse; Issuance of Advisory Opinions by the OIG, 62 FR 7350-01 (Feb. 19, 1997). According to HHS, the final safe harbors “describe practices that are sheltered from liability, even though unlawful intent may be present” and where the “actual intent of the parties is entirely irrelevant.” Id.; see also Medicare and State Health Care Programs: Fraud and Abuse; Clarification of the OIG Safe Harbor Anti-Kickback Provisions, 59 FR 37202-01 (July 21, 1994) (noting that the regulations “describe payments that would be prohibited, where the unlawful intent exists, but for the safe harbor protection that has been granted”).

The safe harbors were thus meant to provide parties with assurance that certain types of business practices would not be subject to enforcement actions under the AKS, regardless of intent. Medicare and State Health Care Programs: Fraud and Abuse; OIG Anti-Kickback Provisions, 56 FR 35952-01, 35983 (July 29, 1991).

Medtronic

In Medtronic, an action brought pursuant to the qui tam provisions of the FCA, see 31 U.S.C. § 3730(b) (permitting whistleblowers known as “relators” to sue persons or entities on behalf of the U.S. for defrauding the government), the relator, Dr. Kuo Chao, alleged that Medtronic, a medical device manufacturer, caused false claims to be filed for services payable by government health care programs by paying kickbacks to physicians to induce and/or reward them for using certain Medtronic devices, in violation of the AKS. See Docket in Civil Action No. 2:17-cv-01903-ODW-SS (hereinafter “Docket”), Entry No. 102.

After the government declined to intervene, and following motion practice regarding the complaint and first amended complaint, the relator filed a third amended complaint that Medtronic moved to dismiss. Id. In its motion, Medtronic argued, inter alia, that the relator’s claims should be dismissed for failure to plead that the subject payments fell outside the AKS’ safe harbors — specifically, the personal services safe harbor, which shelters certain service and management arrangements from liability so long as they meet the requirements set forth in the regulations. See Docket, Entry No. 106, at pp. 16-18. At the time of the alleged violations (prior to the January 2021 amendments to the AKS personal services safe harbor), the requirements of the personal services safe harbor were as follows: (1) the agreement is set out in writing and signed by the parties; (2) the agreement covered all the services the agent provides to the principal and specifies the services to be provided; (3) the agreement specifies exactly the schedule of intervals for services to be provided on a periodic or sporadic basis; (4) the term was not for less than one (1) year; (5) the aggregate compensation was set in advance, consistent with FMV, and was not determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties for which payment may be made under any federal health care program; (6) the services did not involve the counseling or promotion of any arrangement or activity that violated any law; and (7) the services did not exceed those which were reasonably necessary to accomplish the commercially reasonable business purpose of the services. See 42 C.F.R. § 1001.952(d) (effective prior to Jan. 19, 2021).

Though the U.S. had declined to intervene — leaving the relator to litigate on his own pursuant to Title 31 of the U.S. Code, Section 3730(c)(3) — it did submit a statement of interest in response to Medtronic’s motion. See Docket, Entry No. 108. In the statement, the government argued that the motion should be denied because lack of fair market value is not an element of the AKS, and because “FMV, standing alone, is not a defense to the AKS.” Id. at p. 6-8. In urging the court to deny the motion, the government also quoted what it described as the HHS Office of Inspector General’s long-standing warning that under the AKS, “neither a legitimate business purpose for the arrangement, nor a fair market value payment, will legitimize a payment if there is also an illegal purpose.” Id. at p. 7 (citing OIG Supplement Compliance Program Guidelines for Hospitals, 70 Fed. Reg. 4848, 4864 (Jan. 31, 2005)).

The Order Denying Medtronic’s Motion to Dismiss

In an order dated Feb. 24, the court denied Medtronic’s motion to dismiss, agreeing that the relator was not required to set forth the negation of one or more of the elements of the personal services safe harbor with particularity at the pleadings stage, and held that it was plausible that the safe harbor does not apply. See Docket, Entry No. 119, at 10-13.

In so holding, the court embraced many of the government’s assertions from its statement of interest, including that:

As the United States points out, even some fair market value payments will qualify as illegal kickbacks, such as when the payor has considered the volume of reimbursable business between the parties in providing compensation and otherwise intends for the compensation to function as an inducement for more business.

Id. at 12.

The court also stated that the relator’s allegations regarding Metronic’s intent — to reward doctors for using Medtronic devices — if true, would take the payments out of the AKS safe harbor. Id. In reaching its conclusions, the court expressly referenced the long-standing warning cited by the government in the statement of interest. Id.

Analysis

The notion that fair market value on its own is not enough to insulate an arrangement from AKS liability is not controversial — as fair market value is but one of seven requirements that must be met for the personal services safe harbor to apply. The court’s conclusion that improper intent can take the payments out of the safe harbor, however, is notable.

For starters, the personal services safe harbor does not contain an intent element; parties can thus achieve compliance without consideration of subjective intent so long as they meet all the other requirements of this safe harbor. The court’s conclusion here is also contrary to the purpose of the safe harbors — to “describe practices that are sheltered from liability, even though unlawful intent may be present” and where “[t]he actual intent of the parties is entirely irrelevant.” Medicare and State Health Care Programs: Fraud and Abuse; Issuance of Advisory Opinions by the OIG, 62 FR 7350-01, 7351 (Feb. 19, 1997). The order thus challenges the very premise of the safe harbors — the sheltering of certain arrangements from enforcement, regardless of intent.

The Medtronic court’s conclusion regarding the impact of intent on safe harbor protection is based, at least in part, on certain propositions set forth in the government’s statement of interest. In particular, the court appears to have been moved by what the government called “the HHS-OIG’s longstanding warning” that neither legitimate business purposes nor fair market value payment matter if there is also an illegal purpose. See Docket, Entry No. 119, at. 12; see also Docket, Entry No. 108, at 7, citing OIG Supplement Compliance Program Guidelines for Hospitals, 70 Fed. Reg. 4848, 4864 (Jan. 31, 2005). Interestingly, that statement originated from a 2005 document issued by HHS titled “OIG Supplemental Compliance Program Guidance for Hospitals,” in which HHS suggested so-called useful inquiries for hospitals in analyzing arrangements or practices for AKS compliance before taking steps to reduce or eliminate risk — such as ensuring safe-harbor compliance. Id. at 4864. The statement was thus taken out of context and is in fact inapposite, as it relates only to the analysis of arrangements prior to considering the application of potential safe harbors.

While the government did not expressly cite it to support the proposition that improper intent can vitiate safe harbor protection, its reliance thereupon — and its statement of interest generally — certainly implies a more expansive view than HHS’ longer-standing one — that “[t]he actual intent of the parties is entirely irrelevant” to safe harbor analysis.” Id. Regardless, in concluding that improper intent can take a payment out of the safe harbor, the Medtronic court embraced the more expansive view, effectively interpreting the safe harbors as rebuttable presumptions — that can be overcome upon a showing of improper intent — rather than safe harbors that provide assurances against enforcement when met.

Although the order was issued on a motion to dismiss and pertained only to the sufficiency of the pleadings, and though this conclusion itself is arguably dicta, it will no doubt be cited by parties in future cases as standing for the broad proposition that intent can eliminate safe harbor protection. If that happens, this — incorrect — view will thereafter creep into the AKS safe harbor jurisprudence, and in time, could lead to their erosion. The AKS safe harbors were so named intentionally — to provide safety from AKS enforcement for certain otherwise non-abusive arrangements even though unlawful intent may be present.

If courts embrace the view that intent can vitiate safe harbor protection even when the requirements of a safe harbor have been met, the safe harbors will no longer provide meaningful assurances that the business practices they cover are safe from enforcement. Their protections will be upended and ultimately rendered unsafe, despite their name to the contrary.

Categories
news

AEL Wins Appeal at Second Circuit in Securities Class Action Case

On January 11, 2022, AEL partner Ken Abell and associate Scott Glicksman secured a Second Circuit appellate victory for its client, the former CFO of a publicly-traded company, against a class action securities fraud suit against the company and its former officers and directors. At oral argument, the AEL team had argued that an unrelated guilty plea for insider trading (in which AEL also represented the client) did not provide a basis for plaintiffs to assert a viable securities fraud claim in this matter and the dismissal of the case by the district judge should be upheld. The three-judge panel issued a summary order affirming the district court’s dismissal of the action, holding, in part, that our client’s alleged insider trading did not cure the complaint’s pleading deficiencies, and any amendment of the complaint to that effect would be futile. You can read more about the appellate argument here.

Categories
news

AEL Defends Dismissal of Securities Class Action Against Former CFO at Second Circuit

On December 9, 2021, AEL partner Ken Abell and associate Scott Glicksman appeared before the Second Circuit Court of Appeals to argue that the District Judge in the Eastern District of New York properly dismissed a securities class action against AEL’s client, the former CFO of a publicly-traded company. The AEL team argued that an unrelated guilty plea for insider trading (in which AEL also represented the client) did not provide a basis for plaintiffs to assert a viable securities fraud claim in this matter. The team also argued that, as a threshold matter, the District Court correctly held that the plaintiffs did not have standing to assert a claim against AEL’s client given that the plaintiffs purchased shares prior to the improper trades that formed the basis of the client’s insider trading plea.

Categories
news

AEL Gets Probation for Client in Fraud Case

On November 30, 2021, Chief Judge Freda Wolfson of the U.S. District Court for the District of New Jersey sentenced an AEL client to a sentence of probation. The sentencing hearing marks the end of a year-long passport fraud and identity theft investigation. AEL negotiated a plea deal and the client pled guilty in July 2021 to a single count information of making false statements in a passport application. At the sentencing hearing, AEL partner David Eskew and associate Katherine Kulkarni effectively advocated for a probationary sentence highlighting the client’s critical role in his family and his significant history of community engagement and charitable works, among other things. The sentencing was marked by a unique outpouring of support for the client from over a dozen family, friends and community members who attended the hearing. In handing out the probationary sentence, Chief Judge Wolfson weighed the seriousness of the offense against the client’s otherwise “laudable life.” Following the sentencing, the client offered his thoughts on AEL’s representation throughout the case: “It didn’t take more than one phone call with Ken Abell and David Eskew for me to feel confident that I would be in good hands with their firm. People make mistakes, and you want these guys on your side to resolve it. The old cliché “we became like family” was created for a situation like mine with them.” 

AEL is a premier white collar criminal defense and litigation boutique that specializes in complex fraud cases and parallel investigations in the areas of healthcare fraud, securities fraud, bank and wire fraud, and computer fraud as well as qui tam / whistleblower cases and False Claims Act (FCA) cases. AEL is currently representing both individual and institutional clients in investigations and cases throughout the country in both state and federal fora, including the SDNY, EDNY, DNJ, NDNY, NY Attorney General’s Office, New York District Attorney’s Office and the King’s County District Attorney’s Office. AEL partner David Eskew is a former federal prosecutor with civil and criminal experience in both the EDNY and DNJ and served as the Deputy Chief of the Criminal Division and the Chief of the Health Care and Government Fraud Unit in the DNJ. Katherine Kulkarni is an associate of the Firm and previously served as an Assistant District Attorney in the Appeals Division of the New York District Attorney’s Office.        

Categories
news

Law360 Publishes Article Authored by Ken Abell and Kate Kulkarni in Expert Analysis Section Relating to Important FCA Standard

On November 10, 2021, Law360 published an article co-authored by partner Ken Abell and associate Kate Kulkarni in their Expert Analysis Section. The article discusses the deepening Circuit split relating to the standard for government motions to dismiss in False Claims Act (FCA) qui tam actions. As discussed in the article, the Third Circuit adopted the Seventh Circuit’s standard for assessing such motions, which standard is different from either of the two competing standards previously set out by the D.C. Circuit and the Ninth Circuit Courts of Appeal. The full article can be found on our Law Blog or on Law360.  

Categories
news

From Felony Indictment to Misdemeanor Plea and Probation

AEL is proud to announce that on September 14, 2021, a U.S. District Judge for the Eastern District of New York sentenced an AEL client, a pain management doctor with practice locations in Manhattan, Brooklyn and Queens, to 1 year of probation and no fine on a misdemeanor charge for receiving, without knowledge or intent to defraud, a misbranded drug from a foreign source. At the sentencing, the government moved to dismiss a felony indictment it had previously filed, resolving all outstanding charges against the doctor.

The Court’s sentence of probation brings to a conclusion a multi-year investigation and prosecution of the doctor. After a lengthy investigation, the government initially charged the doctor in November 2019 with felony health care fraud in violation of 18 U.S.C. § 1347. In March 2020, a grand jury returned an indictment in which the government alleged over $800,000 in fraudulent billings. Throughout, the doctor consistently maintained his innocence and insisted that any billing errors were just that, mistakes. In the lead-up to trial, AEL attorneys Kenneth M. Abell, David M. Eskew, and Julia H. Sear presented exculpatory evidence to the government that they had found as part of the defense’s investigation and trial preparation. To their credit, the government attorneys ultimately agreed that an alternative resolution was the most appropriate resolution and the doctor pled guilty earlier this year to a non-intent misdemeanor of receiving a misbranded drug.

At sentencing, the government agreed that the prior indictment (and the conduct alleged in that indictment) should not be part of the Court’s sentencing consideration. As part of the doctor’s sentencing submission, multiple of the doctor’s patients submitted letters lauding the doctor for his empathy and work ethic. On September 14, the Court agreed that a short sentence of probation, with no fine, was the appropriate punishment. The client is thrilled with the result and looks forward to returning to his medical practice.

AEL is a premier white collar criminal defense and litigation boutique that specializes in federal parallel criminal and civil healthcare fraud cases on behalf of individuals and institutional clients in the EDNY, SDNY, and DNJ (among other districts across the country), including criminal cases and qui tam cases. Partners Kenneth M. Abell and David M. Eskew are both former federal prosecutors with both civil and criminal experience, and supervised the civil and criminal healthcare practices of their respective offices. Julia H. Sear is an associate of the Firm, with prior experience as an Assistant District Attorney and defense attorney.

Categories
news

AEL Partner Scott R. Landau Recognized by “Best Lawyers in America”

AEL celebrates the announcement that Scott R. Landau was named to the The Best Lawyers in America 2022 list. Scott R. Landau was ranked as a “Best Lawyer” for Health Care Law. This most recent accolade continues a string of recognition for AEL’s elite boutique healthcare practice. Earlier this year, AEL was ranked by Chambers USA as a leading U.S. Healthcare law firm for 2021. Congratulations to Scott on this great recognition!

Categories
news

AEL Ranked as Top Healthcare Firm by Chambers USA

On May 20, 2021, Chambers USA, a world-renowned guide to the legal profession, announced its selection of AEL as a leading U.S. Healthcare law firm for 2021. According to Chambers, AEL is a “well-regarded healthcare boutique” that is “able to practice at the intersection of healthcare and white collar defense;” sources describe AEL as “very attentive and able to get down to the salient facts quickly.”

Chambers also recognized AEL partner Scott R. Landau  as a “ranked lawyer” in Healthcare and describes him as “an extraordinarily insightful litigator” and “an incredibly knowledgeable and excellent healthcare lawyer.”  Scott is the practice leader for AEL’s Healthcare Regulatory & Compliance Counseling, Data Privacy & Security, and Complex Commercial Litigation & Disputes practice areas.

Each year, Chambers acknowledges firms and specific attorneys following a rigorous review and vetting process that entails extensive interviews with lawyers and their clients. Assessments are based on qualities such as technical legal ability, professional conduct, client service, diligence, and commitment. To read more about Chambers and AEL’s firm and individual rankings, please visit https://chambers.com/department/abell-eskew-landau-healthcare-usa-5:62:12806:1:23254203

Categories
news

AEL Negotiates Misdemeanor Plea for Indicted Doctor; Government Agrees to Dismiss Healthcare Fraud Charges; Court Reinstates Doctor’s Billing Privileges

AEL once again navigated a doctor client out of a federal indicted healthcare fraud case, this time in the Eastern District of New York (EDNY). A pain management doctor with practice locations in Manhattan and Queens pled guilty on Thursday, May 6, 2021, to a misdemeanor superseding information charging him with receiving, without knowledge or intent to defraud, a misbranded drug from a foreign source in violation of 21 U.S.C. §§ 331(c) and 333(a)(1). In the plea agreement, the Government agreed to dismiss at the time of sentencing an indictment charging the doctor with a multimillion dollar healthcare fraud scheme. The misdemeanor plea resolves all of the conduct charged in the previously-filed criminal complaint, indictment and superseding information. As part of the plea, the Government agreed and the Court order that the bail condition prohibiting the doctor from billing Medicare and Medicaid be lifted, a restriction that had been in place since the outset of the case.

This incredible resolution for the client comes after intensive negotiations and multiple presentations by AEL to the EDNY U.S. Attorney’s Office in the weeks leading up to trial regarding exculpatory evidence that had been uncovered by AEL attorneys in the course of their internal investigation. The exculpatory evidence, of which the Government had previously been unaware, exonerated the defendant of the primary allegations in the indictment.  

This is the second time in the past three months that AEL has fought back charges in a federal indicted case on behalf of doctor clients. In March 2021, AEL announced that it had successfully negotiated a global resolution of a parallel criminal and civil cases pending in the Southern District of New York (SDNY) against a Manhattan-based vascular surgeon, which charges sprung from a qui tam complaint filed against the doctor. In that case, the Government agreed to a civil-only resolution, resolving its criminal indictment with a deferred prosecution agreement (DPA).

AEL is a premier litigation boutique that specializes in parallel criminal and civil healthcare cases on behalf of individuals and institutional clients in the SDNY, EDNY and DNJ. AEL Partners Kenneth M. Abell and David M. Eskew, both former federal prosecutors and healthcare Chiefs, handled the case.

Categories
news

AEL Steers Parallel Healthcare Fraud Case to Civil-Only Resolution; Obtains DPA in Indicted Case

Abell Eskew Landau LLP (AEL) successfully negotiated the resolution of parallel criminal and civil cases pending in the Southern District of New York (SDNY) against Dr. Feng Qin, a Manhattan-based vascular surgeon. Dr. Qin was previously indicted on healthcare fraud charges over two years ago and had been sued in a parallel civil qui tam action based upon the same alleged conduct. After years under the cloud of federal investigation and two pending cases, the cases finally concluded yesterday with a remarkable result for Dr. Qin. The SDNY United States Attorney’s Office (USAO) agreed to resolve the criminal indictment with a deferred prosecution agreement (DPA). So long as Dr. Qin abides by the terms of the DPA over the next year, the SDNY USAO agreed to dismiss its indictment against Dr. Qin and agreed that no further prosecution would be instituted in the SDNY related to the conduct alleged in the indictment. Separately, Dr. Qin agreed to resolve the civil complaint against him by paying a monetary amount of $783,200, spread out over the course of several years, and by agreeing to a period of Medicare exclusion.

The DPA and civil settlement follow more than a year of intensive negotiations between AEL and the SDNY USAO, which included presentation to the SDNY of several mitigating pieces of evidence on Dr. Qin’s behalf that AEL uncovered as part of its own investigation. As the DPA expressly recognizes, “after a thorough investigation it has been determined that the interest of the United States and [Dr. Qin’s] own interest will best be served by deferring prosecution in this District.” On the civil side, AEL also advocated for a financial inability to pay analysis, which resulted in the substantial reduction of the civil penalty to be paid by Dr. Qin and a lengthy payment plan.

Dr. Qin is a hard-working Chinese immigrant who put himself through medical school in China and again in the United States. Over the years, he built a thriving medical practice that treated largely underserved and needy immigrant communities in Manhattan and Queens. The parallel investigations took a deep emotional and financial toll on Dr. Qin and his family, and he is relieved that the cases have now been finally resolved without the stigma of a criminal conviction and with a potential path, after paying his civil settlement and serving his exclusion period, to resuming his medical practice in the future.  

This case once again highlights AEL’s expertise in navigating complex parallel investigations and litigating healthcare fraud cases and matter arising under the federal and state False Claims Act (FCA). The defense case was led by AEL Partners Kenneth M. Abell and David M. Eskew. You can read more about AEL’s Government Investigations and Enforcement Practice Area, White Collar Criminal Defense Practice Area, and FCA and Whistleblower Litigation Practice Area through the links.

Categories
news

ABA Litigation Journal Publishes Article “Propensity – Persuasion and Prejudice,” Co-Authored by AEL Partner David M. Eskew, in Winter Edition

AEL partner David M. Eskew co-authored an article with colleague Paul Murphy, a partner at Teitler & Teitler, entitled “Propensity – Persuasion and Prejudice: A Look at “Other Acts” Evidence and What the Defense Can Do About It.” The article was originally published in the American Bar Association’s Litigation Journal, Vol. 47, No. 2 (Winter 2021). The article focuses on the practical challenges presented by the admission of propensity evidence in state and federal criminal cases and offers analysis of real-life cases in which such evidence had a featured role. In the article, David and Paul offer practical tips on defending against the dreaded propensity evidence. The article can be read through the link below, in its entirety on our blog, or in the latest edition of the ABA Litigation Journal.

Categories
blog

Propensity – Persuasion and Prejudice: A Look at “Other Acts” Evidence

The following article was originally published in the American Bar Association’s Litigation Journal, Vol. 47 No. 2 (Winter 2021) and was co-authored by AEL partner David M. Eskew and Teitler & Teitler partner Paul Murphy. You can read the article in its full form through the link here, in the post below, or by subscribing to the ABA Litigation Journal.

“He did it before, do you really think he didn’t do it this time?”

This is the stuff of a defense lawyer’s nightmares. Lawyers lose sleep over the notion that, despite all their hard work defending the specific charges in a case, their client’s prior sins will nevertheless be admitted into evidence and take on outsize importance in shaping the jury’s impressions of the client. And for good reason. Evidence of a person’s propensity to act in a certain way can be utterly devastating. Jurors may focus unduly on the prior acts of misconduct to the exclusion of the government’s heavy burden of proof, and they may be more willing to accept other evidence offered against the defendant because it makes more sense, given that, in their minds, the defendant is a bad actor. The converse is often a motivating factor behind the tactic of many white-collar defendants who have otherwise been pillars of the community to parade character witnesses before the jury in fraud cases to testify about the defendant’s reputation for honesty. These witnesses, by design, are selected because they know the defendant as a person and are completely ignorant of the facts of the case. The defense is of course hoping that the jury will conclude that the defendant is trusted by other upstanding members of his or her community so they will be inclined to discredit certain evidence offered against the defendant or to credit certain defenses.

In a slightly different use of propensity evidence, defendants often use what is referred to variously as reverse 404(b) evidence or reverse “other acts” evidence in an effort to lay the blame for the crime they are charged with committing at the doorstep of a third party. They hope that by showing evidence that the third party has committed criminal conduct in the past that is similar to what the defendant is charged with, the jury will have a reasonable doubt as to the culpability of the defendant. The potential for the jury to draw these types of inferences from “other acts” evidence is real. After all, it is human nature to think that we all act consistently with our character traits. Not only does the average person feel these sentiments in their gut, but the concept that an individual may be inclined to act   in accordance with his or her “bad” or “good” character traits is embedded in some of the most consequential areas of criminal law. In the federal system, for instance, a defendant’s prior criminal history is part of a complex calculation used to determine a defendant’s sentencing guidelines range. More generally, federal district courts are obligated to consider a defendant’s “history and characteristics” when fashioning an appropriate sentence. Prosecutors will lean on prior criminal offenses not only in connection with the technical calculation of a defendant’s criminal history score but also as evidence that a greater sentence is needed to promote respect for the law, protect society from further crimes of the defendant, and deter the defendant from future crimes. It would be fundamentally unfair to permit prior criminal acts, both as evidence of a defendant’s general character and as a predictor of future conduct, to increase jail time if there were not some correlation between prior bad acts and future conduct. Defense attorneys attempt to paint a wholly different picture of a defendant by submitting character reference letters designed to persuade the court that a defendant’s crimes of conviction were an aberration not likely to be repeated in the future. In short, propensity is relevant.

But “propensity” is a dirty word when it comes to trial practice. Rule 404(b) of the Federal Rules of Evidence states that “evidence of a crime, wrong, or other act is not admissible to prove a person’s character in order to show that on a particular occasion the person acted in accordance with the character.” Many states have similar rules. These rules apply equally in criminal cases and in civil cases, although the balancing of the probative value against the potential for unfair prejudice may vary between criminal cases and civil ones, especially civil cases that end up in bench trials. One constant, though, is that the rules make it improper to introduce evidence of a defendant’s other bad acts solely to show the defendant’s propensity. Countless court cases and scholars agree on this point, and it is not open for serious debate. Evidence of other bad acts of a defendant may not be used for the sole purpose of showing that a defendant did it before, so he must have done it again. The devil, of course, is in the details, and the real question is whether we practice what we preach. What’s said to be kept out of evidence with a padlock on the front door is regularly let in through the back door. We would be fooling ourselves if we really thought that propensity evidence was not regularly part of trial practice. It is.

This is not to say that prosecutors are acting with unchecked abandon, defying the rules of evidence and asking juries to con- vict purely on the grounds of a defendant’s propensity to be a bad guy. Nor are trial judges necessarily asleep at the switch in permitting such evidence to be admitted in trials. To the contrary, such evidence is expressly permitted by the rules of evidence in appropriate circumstances. Evidence of prior bad acts that is also intrinsic to a charged crime makes a fact that is material to the outcome more likely and therefore is directly relevant to proving the offenses charged. As such, it is generally admissible unless the defense can convince the trial judge that its probative value is substantially outweighed by the danger of unfair prejudice, confusion, or waste of time. Even where it is not intrinsic to the crimes charged, “other acts” evidence is admissible if it satisfies one of the delineated exceptions in Rule 404(b), which expressly permits the admission of “other acts” evidence if such evidence is “admissible for

another purpose,” including “motive, opportunity, intent, prepa- ration, plan, knowledge, identity, absence of mistake, or lack of accident.” These exceptions are expansive. Indeed, commentators have taken the view that the exceptions to the general rule against propensity evidence long ago swallowed the rule. Concepts such as motive, intent, plan, knowledge, and identity are in play in many criminal cases. In cases requiring proof of specific intent, like willfulness, “absence of mistake” and “lack of accident” are often critical parts of the government’s proof.

In determining the admissibility of “other acts” evidence, a federal court employs a well-accepted four-part test: First, the evidence must have a proper evidentiary purpose; second, the evidence must be relevant; third, the evidence must not be more prejudicial than probative; and, fourth, the evidence must be accompanied by a limiting instruction if requested. Despite the safeguards built into the rules of evidence to try to avoid the prejudice that naturally flows from propensity evidence, one would be well within his or her rights to question whether evidence admitted for a proper, non-propensity purpose is nevertheless grounded in what we regularly think of as “propensity.” Regardless of the label affixed to it or the purpose for which it is legitimately offered, the fact is that all such evidence is relevant because it raises inferences that are based on a defendant’s propensity to act in a certain way. There is no way to completely avoid it. If, for instance, “other acts” evidence is offered to show that, on a prior occasion a defendant used a similar method to knowingly defraud someone, in order to show that on the occasions charged the defendant knew he was committing  a fraud and was not acting in good faith, isn’t that just another way of asking the jury to conclude that he did it before and he must have known it was wrong this time?

“Other Acts” Evidence Has Become Routine in Criminal Trials

How has “other acts” evidence become such a routine part of criminal trials? The answer is multifaceted. First, evidence of other bad acts is often cast as direct or intrinsic evidence. Prosecutorial charging decisions can shape what counts as relevant evidence. Charging a case as a conspiracy or crime premised on a scheme or pattern, for instance, may allow prosecutors to offer into evidence other acts of misconduct by a defendant that would otherwise have been thought of as propensity evidence because such evidence becomes inextricably intertwined with the charged offenses. In this way, uncharged acts of securities fraud or health care fraud, when characterized as part of an overarching charged scheme or conspiracy, are generally admissible to prove the scheme or conspiracy. Likewise, “other acts” evidence may be admitted to complete the story of the charged crime without being subject to the scrutiny of Rule 404(b). Even if the

evidence is not intrinsic to the charged offenses or necessary to complete the story, a defendant’s other acts are often admitted to show knowledge, motive, a particular modus operandi, or to blunt a defense—especially where a defendant claims that what she did was simply a mistake, an aberration, or otherwise done without criminal intent. Casting prior bad acts evidence as rel- evant to prove knowledge or intent—an element in nearly every criminal offense—brings such evidence into play in almost every conceivable case.

In federal courts, “other acts” evidence regularly becomes an issue in white-collar fraud prosecutions due to the heightened mental state required to prove such crimes beyond a reasonable doubt. Securities fraud, health care fraud, and other federal fraud offenses generally are specific-intent crimes requiring a showing of knowing and willful acts done with an intent to defraud. Conduct is not willful or committed with fraudulent intent if the defendant “acted through negligence, mistake, accident, or due to a good faith misunderstanding of the requirements of the law.” Such crimes are particularly susceptible to defenses of good faith, honest mistake, and lack of fraudulent intent.

This is regularly on display in the corporate fraud context. Senior executives of successful multinational corporations, who in the normal course are prone to hold themselves out as masters of the universe, regularly present defenses in criminal securities fraud prosecutions that are based on the notion that they were unable to fully grasp pertinent concepts of finance, accounting, and law. Instead, they contend that they relied in good faith on professionals such as accountants, finance executives, and lawyers to assure them that what the corporation did was legal. The defense is often some combination of lack of knowledge of the operative facts and a good-faith belief that the corporation was not, in fact, cheating.

These types of defenses were prominent in the wave of ac- counting fraud scandals that followed the implosion of Enron. Executives began pleading ignorance of the fraudulent aspects of various earnings management practices. Roundtrip transactions where no risk was transferred and other accounting gimmicks used to prop up quarterly earnings and financial statements were said to have been blessed by armies of high-paid accountants and lawyers. These defenses can be difficult to penetrate be- cause corporate chieftains often insulate themselves from the dirty work that happens in their organizations. The government chips away at the defenses in a variety of ways. One is through evidence of other acts of misconduct tending to show that the executives knew they were cheating and were inclined either to break the rules or turn a blind eye to obvious problems. Indeed, the government sought to introduce 404(b) evidence against Enron chairman and chief executive officer Kenneth Lay relating to his knowledge of a prior fraud scheme involving deceptive trading at an Enron subsidiary over a decade earlier to show his knowledge, intent, absence of mistake, motive, and modus operandi concerning the securities and other fraud charges that led to the downfall of Enron. It is worth noting that corporate fraud defendants have had at least some success in keeping “other acts” evidence out of trials by convincing the trial court that the evidence would be marginally relevant and unduly prejudicial and would risk diverting the jury’s attention from the central issues by creating a trial within a trial.

Criminal Tax Fraud Cases

Nowhere is the government’s burden higher than in criminal tax fraud cases, which the Supreme Court has held require the government to prove beyond a reasonable doubt that the defendant knew he was breaking the law. The Court held that even a mistaken and inherently unreasonable belief that the law did not require taxes to be paid on income would be a defense if the jury found that the defendant in good faith believed it to be the state of the law. Cheek v. United States, 498 U.S. 192, 203 (1991). Given the government’s high burden, tax cases regularly involve what would otherwise be considered “other acts” evidence. Imagine a case in which the defendant is charged with tax fraud for filing false tax returns for the calendar years 2018 and 2019. The government must not only prove that the defendant acted knowingly in 2018 and 2019, those tax years charged directly in the indictment, but must also be prepared to blunt the defense that the defendant was negligent, sloppy, unwitting, disorganized, or just plain ignorant. As a result, the government can be expected to mine the defendant’s prior tax filings to find some evidence that the defendant was aware of some requirement not met in the charged tax years. Perhaps the defendant previously recognized some revenue in connection with a Schedule C business that she did not in the charged tax years or did not take a deduction or credit that is now claimed in the charged tax years. In this scenario, the government will likely argue that the prior tax returns are intrinsic evidence—not 404(b) evidence  at all—necessary to prove that the taxpayer defendant had the requisite knowledge and understanding of the tax laws to satisfy its burden of proving willfulness. More to the point, if the prior tax returns show a similar pattern as the charged tax years, the government will seek to introduce the tax returns from prior years as evidence that the defendant acted knowingly and willfully with respect to the years charged.

Sexual Assault Cases

More recent developments in the area of “other acts” evidence demonstrate that society is especially unwilling to allow defendants with prior histories of particularly heinous acts to cloak themselves in defenses of mistake and the like. Sexual assault cases have been found to warrant this type of special consideration. In federal sex crime cases, the rules clearly favor the admissibility of “other acts” evidence. Specifically, Federal Rules of Evidence 413 and 414 expressly permit the introduction of evidence of prior bad sex acts in sexual assault cases. States have recently demonstrated a willingness to entertain more of this type of “other acts” evidence in cases involving sexual assault, applying their existing rules in a seemingly broader way to permit such evidence.

Recent high-profile trials arising out of the #MeToo movement relied heavily on evidence of other acts of sexual assault. These cases illustrate the manner in which other bad acts evidence may be introduced at trial and the devastating effect of such evidence in sexual assault cases.

Harvey Weinstein, for instance, was charged with rape and sexual assault against two victims. The indictment also included a count charging him with being a sexual predator, making the testimony of a third victim directly relevant to prove the predatory aspect of the charge, an element of the offense that the prosecution was required to prove beyond a reasonable doubt. The prosecution also sought to offer the testimony of three additional witnesses to testify about their allegations that Weinstein sexually assaulted them. This testimony did not result in charged offenses but clearly fell into the category of “other acts” evidence of the defendant. After a pretrial hearing that was closed to the public, the trial court permitted the government to call these additional witnesses.

In New York, where Weinstein was tried, such witnesses are known as Molineux witnesses after the seminal 1901 New York Court of Appeals case that spawned much of the law nationwide concerning “other acts” evidence. In the Molineux case, the court reversed the conviction of a doctor charged with the very 19th-century crime of murder by poisoning because the trial court had permitted testimony about another similar incident. The importance of such evidence to a conviction is illustrated by that very case. The defendant there was convicted at his first trial when the trial court allowed evidence of a prior effort by him to commit another murder using the same pattern. Reporting indicates that, after the conviction was reversed, the defendant was tried a second time without the prior acts evidence, and the jury acquitted.

In Harvey Weinstein’s trial, the “other acts” evidence was likely of a similar value to the prosecution. Public reporting about the Molineux witnesses there indicated that they offered highly damaging testimony against the defendant. His counsel has said publicly that they intend to make the introduction of these three additional witnesses a central focus of their appeal.

While the nature of our system is such that we rarely learn why the jury chose to do what it did, one interesting aspect of the Weinstein trial is that the jury acquitted him of the count of being a sexual predator, where it would have had to accept the testimony of the third sexual assault victim beyond a reasonable doubt because her testimony was effectively an element of a count of the indictment. But the jury did not necessarily have to apply the same standard of proof to its evaluation of the Molineux witnesses’ accounts in order to use their testimony to support the conclusion that Weinstein was guilty. This is so because a defendant’s involvement in other bad acts generally need not be established beyond a reasonable doubt for a jury to consider it. In the federal system, the Supreme Court has held that, to admit the “other acts” evidence, the district court need find only that the trier of fact could conclude that the evidence demonstrates by a preponderance that the other acts occurred and that the defendant participated in them. See Huddleston v. United States, 485 U.S. 681, 685 (1988).

The value of such propensity evidence was also on full display in the case against Bill Cosby. Cosby’s first trial ended in a hung jury after the trial court permitted only one “prior act” witness to testify about another uncharged instance of sexual assault by the defendant. At the retrial, the court permitted the prosecution to call five other victims who testified about similar, uncharged conduct by the defendant. This evidence was offered to show that Cosby engaged in a common plan, scheme, or design—essentially, that Cosby had engaged in a particular modus operandi when committing the offense charged—and that their testimony demonstrated that his conduct was not the product of a mistaken belief that the sex was consensual. With this additional evidence reflecting other criminal acts, the jury convicted on the retrial. And the intermediate appellate court in Pennsylvania recently upheld the conviction against a challenge based in large measure on the introduction of this “other acts” evidence. Propensity evidence can raise its head in less traditional, but equally damaging ways. Prosecutors can capture other acts of the defendant by simply charging other bad acts in separate counts of the indictment, even if only loosely related to the top counts.

Doing so places additional pressure on the defendant and nearly ensures that damaging and possibly highly prejudicial evidence against the defendant will be admissible at trial.

“Joe Exotic” and Propensity Evidence

The manner in which other seemingly unrelated acts can be charged in a single indictment can be observed in the trial of Joseph Maldonado-Passage, also known as “Joe Exotic,” the so-called “Tiger King” from the wildly popular Netflix documentary of the same name. Federal prosecutors initially charged Maldonado-Passage with two counts of using an interstate facility to commit murder for hire in connection with his alleged efforts to murder a conservationist who had for years dogged Maldonado-Passage’s operation of a “roadside zoo” in Oklahoma. A few months after his initial indictment and in advance of trial, the government added 19 additional counts, all related to Maldonado-Passage’s alleged mistreatment of exotic animals at his zoo. The wildlife counts were supported by gruesome evidence, including tiger skulls excavated from the zoo’s property that belonged to big cats Maldonado-Passage was said to have euthanized and buried.

Though loosely related to the top count, the additional counts ensured that the government would be able to introduce extensive and detailed evidence regarding Maldonado-Passage’s mistreatment, breeding, and sale of numerous exotic cats. Though of lesser severity than the murder-for-hire plot (certain of the counts under the Endangered Species Act were misdemeanors), the animal mistreatment counts were, no doubt, supported by much stronger evidence than the murder-for-hire plot and were highly prejudicial. As noted by a journalist covering the trial, “[i]n the news, we talk about shootings and killings every day. But people will protest and they will not tolerate animal abuse. It was almost strategic to bring all of these charges at the same time.”

Arguing against the admissibility of such evidence is a tall task that is most often unsuccessful. Defense attorneys are limited to arguing that the introduction of certain “intrinsic” evidence or the joinder of certain counts is merely pretextual and that the government is attempting to shoehorn propensity and otherwise inadmissible “bad character” evidence into its case in chief. For example, in the “Tiger King” trial, defense attorneys argued that the murder-for-hire counts should be severed from the so-called wildlife counts. In their motion, defense attorneys contended that the evidence in support of the wildlife counts “would not be admissible in the government’s case in chief in the trial of the murder for hire charges” and that “[s]uch evidence will ir- reparably prejudice the jury beyond any curative effect of a jury instruction.” The defense went on to argue that “[t]he prejudicial effect of evidence relating to alleged slaughter of beloved ani- mals in a trial for a murder for hire plot is clear and substantial, particularly when Mr. Maldonado-Passage’s public identity is well known as an operator of an exotic zoo.”

But the rules regarding the joinder of counts and relevance generally are permissive, and relief is rarely granted. In the “Tiger King” case, defense counsel’s motion played out in a familiar unsuccessful pattern. The government opposed the motion, arguing that the murder-for-hire counts and the wildlife counts were part of a common scheme and plan, all of which were related to Maldonado-Passage’s long-standing feud with the conservationist victim, including her efforts to collect on civil judgments she had obtained against him, and the defendant’s efforts to profit from his roadside zoo that featured and bred big cats. By tying the more severe murder-for-hire counts with Maldonado-Passage’s businesses, finances, and long-standing feud with conservationist groups, the government was easily able to articulate a basis for charging all of the conduct together in a single indictment. The court agreed that the counts were interconnected and properly joined and denied the defendant’s pretrial motion.

The government also used “other acts” evidence during the “Tiger King” trial. In that case, the government introduced testimony about prior conversations Maldonado-Passage had with others regarding the victim’s assassination, along with a litany of social media posts and videos that Maldonado-Passage had made about his would-be conservationist victim. In the posts, Maldonado-Passage was alleged to have used direct and graphic language, repeatedly referring to her murder, including bizarre and grisly methods such as venomous snakes and decapitation. As the prosecutor noted in the documentary, “[i]t was part of the government’s evidence that we showed the jury a variety of the social media postings that Mr. Passage had made that referenced [the victim] in a violent way—having her killed, or wishing her dead.” The justification for the admission of such evidence was that the evidence showed the defendant’s motive, intent, and plan related to the charged murder-for-hire plot.

As can be seen from the examples above, the “proper purposes” for the admission of “other acts” evidence are numerous and the standards of relevance are broad. For that reason, there are many avenues for the admission of such evidence, and the standard for admission is often easily satisfied. While courts do what they can to police the use of this type of evidence, the reality is that once “other acts” evidence comes in—even for a stated non-propensity purpose—there is no controlling how a jury will view it. Limiting instructions are likely only to confuse the jury and cause them to fall back on what comes naturally to them—if the defendant did it before, he’s more likely to have done it again. Courts, including the Supreme Court, and commentators have long questioned the effectiveness of limiting instructions in situations where compliance with such an instruction would require a particularly difficult form of “mental gymnastics.” It could be argued that it is simply too much to ask human beings to put aside everything they have used over the course of their lives to evaluate people—namely, judging them by what they have done in the past. This is especially evident when jury instructions also separately advise juries to use their common sense when judging, among other things, the weight of the evidence. People view others as liars because they have lied in the past. Others are considered cheats because they have cheated in the past. We ask jurors to bring their common sense and life experience to the courtroom to judge the facts of a case, but when it comes to propensity evidence, we ask them to do exactly the opposite. Put aside your life experience and your tried-and-true methods of judging circumstances and people, and limit how you think about the fact that the defendant com- mitted the very crime he is charged with on a prior occasion. Do we really think that everyday people can put these issues aside?

What the Defense Can Do

What is a defense lawyer to do? Given the potential prejudice inherent in this type of evidence, defense counsel must make every effort to persuade a trial judge that the evidence is not properly admissible. Step one of course is a challenge to the proper purposes the government seeks to offer it for and to take aim at the relevance of the evidence. Courts do often reject government bids to offer “other acts” evidence on the threshold ground that it does not actually satisfy one of the exceptions in Rule 404(b) or that it is simply not relevant to the issues charged in the case. Failing that, the best argument defense counsel can deploy is that the “other acts” evidence will be unfairly prejudicial.

In the federal system, Rule 403 is the rule that gives a trial judge wide discretion to preclude otherwise relevant evidence onthe grounds of “unfair prejudice, confusing the issues, mislead- ing the jury, undue delay, wasting time, or needlessly presenting cumulative evidence.” Defense lawyers must hammer away at the unfairness of the prejudice. Facts such as remoteness in time, infrequency of conduct, a lack of similarity between the “other acts” and the charged conduct, intervening conduct or events, and the need for extensive additional testimony or evidence—the so-called “trial within a trial”—are all powerful arguments that the other acts sought to be admitted are more prejudicial than probative and are likely simply to confuse the issues and the jury. Indeed, it is often the case that the prosecution’s proof of the defendant’s involvement in the other bad acts is somewhat diffuse or the proofs of the other acts thin. But it is not enough to argue that evidence is prejudicial. It must be “unfairly” prejudicial. In other words, counsel must make the case that the “other acts” evidence would cause the jury to base its decision on something other than the evidence in the case. For this point, counsel can argue that the evidence would confuse, distract, or incite the passions of the jury to such an extent as to taint their consideration of the core issues in the case. In sum, defense counsel needs to be constantly vigilant to try to keep out “other acts” evidence. This should be done through carefully crafted pretrial motions and a clear trial plan that avoids opening any doors to such evidence. Some “other acts” evidence may be truly harmless and weak by nature, so the worry that the jury will do anything with it is overstated. But when it comes to highly damaging prior acts of a defendant, the admission of such evidence for a proper evidentiary purpose has the potential to carry such damaging effects that counsel should make all efforts to keep such evidence out. Counsel should not hold anything back at the trial level, as appellate courts will review a district court’s decision to admit such evidence for an abuse of discretion. In the federal system, if a district court considers all the evidence and arguments when weighing the probative value against the prejudicial impact and decides to admit the evidence, an appellate court will be loath to overturn a guilty verdict on that ground. And if such evidence is admitted, the defense counsel must work hard to limit the prejudicial impact of the evidence. Point out the weaknesses in the proof regarding those prior bad acts, and argue the dangers of reading too much into other acts that are not directly related to the charged offenses. And maybe, just maybe, tell the jury, “Just because he did it before, doesn’t mean he did it again.”

Categories
news

AEL obtains DPA from SDNY U.S. Attorney’s Office in Indicted Case.

Abell Eskew Landau LLP (AEL) is proud to announce that it has obtained for its client, Dr. Feng Qin, a Deferred Prosecution Agreement (DPA) from the United States Attorney’s Office (USAO) for the Southern District (SDNY). Dr. Qin was previously indicted over two years ago with one felony count of health care fraud. So long as Dr. Qin complies with the terms of the DPA, which include entering into a civil settlement agreement and refraining from violating the law, the government has agreed to dismiss the indictment and no further prosecution will be instituted in the SDNY related to the conduct alleged in the indictment.

The DPA follows more than a year of intensive discussions, during which AEL presented mitigating and exculpatory evidence to the SDNY, and expressly recognizes that the government ultimately “determined that the interest of the United States and [Dr. Qin’s] own interest [are] best served by deferring prosecution in this District.” Dr. Qin is happy to move on with his life and career without a criminal conviction.

AEL founding partners Kenneth M. Abell and David M. Eskew, who served as lead counsel on Dr. Qin’s case, previously served as federal prosecutors and chiefs of the civil healthcare fraud unit in the U.S. Attorney’s Office for the Eastern District of New York (EDNY) and the criminal healthcare fraud unit in the U.S. Attorney’s Office for the District of New Jersey (DNJ), respectively, and are expert at handling parallel investigations and cases. As these results show, AEL is uniquely positioned to navigate parallel investigations and prevail upon the government that in appropriate circumstances civil resolutions can best serve justice. AEL currently represents multiple institutions and individuals (including physicians) in the midst of parallel federal investigations (both pre and post-charge), and in every case works tirelessly to achieve favorable outcomes for our clients.

Categories
news

AEL Negotiates Favorable Resolution to Multi-Year NYAG Investigation; Client Praises AEL Partner Ken Abell as “Above and Beyond.”

AEL is proud to announce the successful resolution of a multi-year investigation involving one of its individual clients, a prominent New York-based obstetrician/gynecologist. On November 16, 2020, AEL finalized a highly favorable civil resolution with the New York Attorney General’s Office (NYAG). The case arose from a years-long investigation by the NYAG under the New York State version of the False Claims Act. After years of investigation and months of negotiation, AEL ultimately convinced the State to resolve the matter as a relatively small overpayment, instead of a False Claims Act violation, with no admissions by the client of wrongdoing, no penalties, and no exclusion from billing the Medicaid program. The client stated, “Ken Abell and his team recently represented me in a case brought against me by a government agency. I must say his representation of me went above and beyond your typical law firm. He understood my concerns that I was being treated unfairly and went the extra mile to settle the case in my favor. I am sure I would have had a much worse result with other legal representation. I highly recommend him and his team if you need his field of law. I know I will call him for my next legal need. I have already recommended his firm to another friend.” AEL prides itself of client-focused representation and excels at representing both institutions and individuals in parallel civil/criminal enforcement actions and investigations, especially in the healthcare industry. AEL Partner Ken Abell was lead counsel on the case.

Categories
news

AEL Partner Scott R. Landau quoted in Law360 Article About Fiduciary Duties of General Counsel

Abell Eskew Landau LLP partner Scott R. Landau commented today in a Law360 article concerning the upcoming trial of ex-Theranos CEO Elizabeth Holmes. Defense counsel has asserted a mental health defense in the upcoming and much-anticipated March trial in the Northern District of California federal court. In this article, Scott R. Landau weighs in on the difficult question of the fiduciary duties of a general counsel to a company’s board of directors when the CEO is in crisis. Read the full article through the link below.

Categories
news

Law360 Features Expert Analysis by AEL Founding Partner Kenneth M. Abell Regarding False Claims Act (FCA) “Original Source” Decision

On June 6, 2020, Law360 featured an Article by AEL founding partner Kenneth M. Abell in their Expert Analysis Section. The Article, entitled “FCA Ruling Shows Importance Of Relator As Original Source” dissects the recent decision by the U.S. Court of Appeals for the Second Circuit in U.S. ex rel. Hanks v. Florida Cancer Specialists, which reversed and remanded a decision by the District Court for the Eastern District of New York. In the Hanks decision, the Second Circuit analyzed the well-tread (and still highly important) False Claims Act (FCA) concepts of the public disclosure bar, the first-to-file rule, and the original source exception. Follow this link to read the Article. AEL’s three founding partners all served as Assistant U.S. Attorneys and each conducted multiple, sophisticated, high stakes parallel investigations under the False Claims Act (FCA). As a result, AEL has extensive expertise in the False Claims Act and white collar civil and criminal government investigations and enforcement actions. AEL represents major hospital systems and other private companies in high stakes qui tam / whistleblower actions and commercial litigation.